These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 30689009)
1. [Antithrombotic treatment in acute coronary syndrome and atrial fibrillation]. Darius H; Görge G; Spiecker M; Schinzel H Herz; 2019 Feb; 44(1):29-34. PubMed ID: 30689009 [TBL] [Abstract][Full Text] [Related]
2. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation]. Darius H Dtsch Med Wochenschr; 2020 Jul; 145(14):978-986. PubMed ID: 32668469 [TBL] [Abstract][Full Text] [Related]
3. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials? Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144 [TBL] [Abstract][Full Text] [Related]
4. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy. Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352 [TBL] [Abstract][Full Text] [Related]
5. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Potpara TS; Mujovic N; Proietti M; Dagres N; Hindricks G; Collet JP; Valgimigli M; Heidbuchel H; Lip GYH Europace; 2020 Jan; 22(1):33-46. PubMed ID: 31603196 [TBL] [Abstract][Full Text] [Related]
6. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Park J; Jung JH; Choi EK; Lee SW; Kwon S; Lee SR; Kang J; Han KD; Park KW; Oh S; Lip GYH PLoS One; 2022; 17(2):e0264538. PubMed ID: 35213632 [TBL] [Abstract][Full Text] [Related]
7. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Fanaroff AC; Lopes RD Prog Cardiovasc Dis; 2021; 69():11-17. PubMed ID: 34883097 [TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. Lopes RD; Hong H; Harskamp RE; Bhatt DL; Mehran R; Cannon CP; Granger CB; Verheugt FWA; Li J; Ten Berg JM; Sarafoff N; Gibson CM; Alexander JH JAMA Cardiol; 2019 Aug; 4(8):747-755. PubMed ID: 31215979 [TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Kuno T; Ueyama H; Takagi H; Ando T; Numasawa Y; Briasoulis A; Fox J; Bangalore S Am J Cardiol; 2020 Feb; 125(4):521-527. PubMed ID: 31839147 [TBL] [Abstract][Full Text] [Related]
10. Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy? Fluschnik N; Becher PM; Schnabel R; Blankenberg S; Westermann D Herz; 2018 Feb; 43(1):20-25. PubMed ID: 29188358 [TBL] [Abstract][Full Text] [Related]
11. Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen. Kawakami S; Yasuda S; Ogawa H J Cardiol; 2020 Jul; 76(1):35-43. PubMed ID: 32389534 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. Vranckx P; Lewalter T; Valgimigli M; Tijssen JG; Reimitz PE; Eckardt L; Lanz HJ; Zierhut W; Smolnik R; Goette A Am Heart J; 2018 Feb; 196():105-112. PubMed ID: 29421002 [TBL] [Abstract][Full Text] [Related]
13. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160 [TBL] [Abstract][Full Text] [Related]
14. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH; Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056 [TBL] [Abstract][Full Text] [Related]
15. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085 [TBL] [Abstract][Full Text] [Related]
16. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853 [TBL] [Abstract][Full Text] [Related]
17. Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us? Lam DH; Bell SM; Hira RS Curr Atheroscler Rep; 2018 Jan; 20(1):4. PubMed ID: 29349596 [TBL] [Abstract][Full Text] [Related]
18. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. Vranckx P; Valgimigli M; Eckardt L; Lewalter T; Unikas R; Marin F; Schiele F; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Tijssen J; Goette A Eur Heart J; 2020 Dec; 41(47):4497-4504. PubMed ID: 32860041 [TBL] [Abstract][Full Text] [Related]
19. Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS. Badjatiya A; Rao SV Curr Cardiol Rep; 2019 Jan; 21(1):3. PubMed ID: 30637536 [TBL] [Abstract][Full Text] [Related]
20. Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. Lopes RD; Hong H; Harskamp RE; Bhatt DL; Mehran R; Cannon CP; Granger CB; Verheugt FWA; Li J; Ten Berg JM; Sarafoff N; Vranckx P; Goette A; Gibson CM; Alexander JH JAMA Cardiol; 2020 May; 5(5):582-589. PubMed ID: 32101251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]